G.I. Research Institute
Welcome,         Profile    Billing    Logout  
 3 Trials 
11 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bressler, Brian
VERDICT, NCT04259138 / 2019-002485-12: Determination of the Optimal Treatment Target in Ulcerative Colitis

Active, not recruiting
4
672
Europe, Canada, US, RoW
Treatment Algorithm A, vedolizumab, Treatment Algorithm B, Treatment Algorithm C
Alimentiv Inc., Takeda Development Center Americas, Inc.
Colitis, Ulcerative
03/26
03/26
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting
2
268
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Crohn's Disease
09/26
07/27
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
207
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Ulcerative Colitis
09/26
08/27
Colman, Mari Chris
VERDICT, NCT04259138 / 2019-002485-12: Determination of the Optimal Treatment Target in Ulcerative Colitis

Active, not recruiting
4
672
Europe, Canada, US, RoW
Treatment Algorithm A, vedolizumab, Treatment Algorithm B, Treatment Algorithm C
Alimentiv Inc., Takeda Development Center Americas, Inc.
Colitis, Ulcerative
03/26
03/26
Ko, Hin Hin
NCT05677971: Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Recruiting
3
160
Europe, Canada, US, RoW
Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo, Sodium chloride
Takeda, Takeda Development Center Americas, Inc.
Alpha1-Antitrypsin Deficiency
03/27
03/29
NCT03954327: Combination Antiretroviral Therapy (cART) for PBC

Completed
2
37
Canada
Emtricitabine (FTC)/Tenofovir Disoproxil (TDF), Truvada, Raltegravir, Isentress, Placebo Oral Capsule [CEBOCAP], placebo
University of Alberta, Merck Sharp & Dohme LLC
Primary Biliary Cholangitis
10/22
01/24
PACIFIC, NCT05525520 / 2021-002526-25: Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis

Completed
2
62
Europe, Canada, US, RoW
EP547, Placebo
Escient Pharmaceuticals, Inc, Escient Pharmaceuticals, Inc.
Pruritus
07/24
09/24
RESOLVE, NCT05608681: A Trial to Evaluate EP-104IAR in Adults With Eosinophilic Esophagitis (EoE).

Recruiting
1/2
57
Europe, Canada, RoW
EP-104IAR
Eupraxia Pharmaceuticals Inc.
Eosinophilic Esophagitis
12/25
12/25
Zobel, Joshua
EvolvE, NCT05774184 / 2022-001786-12: A Study of CDX-0159 in Patients With Eosinophilic Esophagitis

Active, not recruiting
2
86
Europe, Canada, US, RoW
barzolvolimab, Matching Placebo
Celldex Therapeutics, Celldex Therapeutics, Inc.
Eosinophilic Esophagitis
06/25
12/25
RESOLVE, NCT05608681: A Trial to Evaluate EP-104IAR in Adults With Eosinophilic Esophagitis (EoE).

Recruiting
1/2
57
Europe, Canada, RoW
EP-104IAR
Eupraxia Pharmaceuticals Inc.
Eosinophilic Esophagitis
12/25
12/25
Yamamoto, Leo
RESOLVE, NCT05608681: A Trial to Evaluate EP-104IAR in Adults With Eosinophilic Esophagitis (EoE).

Recruiting
1/2
57
Europe, Canada, RoW
EP-104IAR
Eupraxia Pharmaceuticals Inc.
Eosinophilic Esophagitis
12/25
12/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bressler, Brian
VERDICT, NCT04259138 / 2019-002485-12: Determination of the Optimal Treatment Target in Ulcerative Colitis

Active, not recruiting
4
672
Europe, Canada, US, RoW
Treatment Algorithm A, vedolizumab, Treatment Algorithm B, Treatment Algorithm C
Alimentiv Inc., Takeda Development Center Americas, Inc.
Colitis, Ulcerative
03/26
03/26
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting
2
268
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Crohn's Disease
09/26
07/27
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
207
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Ulcerative Colitis
09/26
08/27
Colman, Mari Chris
VERDICT, NCT04259138 / 2019-002485-12: Determination of the Optimal Treatment Target in Ulcerative Colitis

Active, not recruiting
4
672
Europe, Canada, US, RoW
Treatment Algorithm A, vedolizumab, Treatment Algorithm B, Treatment Algorithm C
Alimentiv Inc., Takeda Development Center Americas, Inc.
Colitis, Ulcerative
03/26
03/26
Ko, Hin Hin
NCT05677971: Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Recruiting
3
160
Europe, Canada, US, RoW
Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo, Sodium chloride
Takeda, Takeda Development Center Americas, Inc.
Alpha1-Antitrypsin Deficiency
03/27
03/29
NCT03954327: Combination Antiretroviral Therapy (cART) for PBC

Completed
2
37
Canada
Emtricitabine (FTC)/Tenofovir Disoproxil (TDF), Truvada, Raltegravir, Isentress, Placebo Oral Capsule [CEBOCAP], placebo
University of Alberta, Merck Sharp & Dohme LLC
Primary Biliary Cholangitis
10/22
01/24
PACIFIC, NCT05525520 / 2021-002526-25: Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis

Completed
2
62
Europe, Canada, US, RoW
EP547, Placebo
Escient Pharmaceuticals, Inc, Escient Pharmaceuticals, Inc.
Pruritus
07/24
09/24
RESOLVE, NCT05608681: A Trial to Evaluate EP-104IAR in Adults With Eosinophilic Esophagitis (EoE).

Recruiting
1/2
57
Europe, Canada, RoW
EP-104IAR
Eupraxia Pharmaceuticals Inc.
Eosinophilic Esophagitis
12/25
12/25
Zobel, Joshua
EvolvE, NCT05774184 / 2022-001786-12: A Study of CDX-0159 in Patients With Eosinophilic Esophagitis

Active, not recruiting
2
86
Europe, Canada, US, RoW
barzolvolimab, Matching Placebo
Celldex Therapeutics, Celldex Therapeutics, Inc.
Eosinophilic Esophagitis
06/25
12/25
RESOLVE, NCT05608681: A Trial to Evaluate EP-104IAR in Adults With Eosinophilic Esophagitis (EoE).

Recruiting
1/2
57
Europe, Canada, RoW
EP-104IAR
Eupraxia Pharmaceuticals Inc.
Eosinophilic Esophagitis
12/25
12/25
Yamamoto, Leo
RESOLVE, NCT05608681: A Trial to Evaluate EP-104IAR in Adults With Eosinophilic Esophagitis (EoE).

Recruiting
1/2
57
Europe, Canada, RoW
EP-104IAR
Eupraxia Pharmaceuticals Inc.
Eosinophilic Esophagitis
12/25
12/25

Download Options